Novo Nordisk(US:NVO) 智通财经网·2026-01-04 05:44Core Viewpoint - The Supreme People's Court of China made a favorable ruling regarding the patent of semaglutide, which is a significant development for Novo Nordisk, reflecting the Chinese government's strong support for pharmaceutical innovation [1] Group 1: Company Impact - Novo Nordisk expressed joy over the court's decision, which reinforces the validity of the semaglutide patent and enhances the confidence of foreign enterprises in sustainable development in China [1] - The CEO of Novo Nordisk highlighted that this ruling will further promote the research and introduction of innovative drugs, benefiting patients [1] Group 2: Product Information - Semaglutide is a novel long-acting GLP-1 analog developed by Novo Nordisk, serving as the main component in weight management drug Wegovy and type 2 diabetes treatment drugs Ozempic and Rybelsus [1] - Since its launch, semaglutide has gained widespread clinical recognition, accumulating approximately 38 million patient-years of usage experience [1] Group 3: Market Expectations - Novo Nordisk previously indicated that the expiration of the semaglutide patent in certain international markets is expected to have a low single-digit negative impact on the company's global sales growth in 2026, and this ruling does not alter that expectation [1]